MetaCap

Cingulate (CING) vs Fortress Biotech (FBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cingulate (CING) has outperformed Fortress Biotech (FBIO) over the past year, gaining 27.8% versus a loss of 26.6%. Cingulate is the larger company by market cap ($67.5 million vs $64.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CING+27.76%FBIO-26.64%
+244%+98%-47%
Nov 21, 20251 yearNov 20, 2026
CING-99.49%FBIO-95.22%
+5%-50%-105%
Dec 6, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CING versus FBIO key metrics
MetricCINGFBIO
Share price$4.51$1.90
Market cap$67.48M$64.11M
1-day change-14.26%+7.34%
YTD return+3.92%-48.09%
1-year return+27.76%-26.64%
5-year return—-95.52%
P/E ratio (TTM)—0.83
EPS (TTM)$-2.67$2.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$63.26M
Revenue growth (YoY)—+9.69%
Net income (latest FY)$-22.45M$6.82M
Gross margin—66.92%
Operating margin—-111.00%
Net margin—10.77%
52-week high$11.89$4.53
52-week low$3.16$1.64
Distance from 52-week high-62.07%-58.06%
Analyst consensusnonenone
Avg. price target upside+370.07%+163.16%
Average volume178.82K281.49K
Shares outstanding14.96M33.74M
Employees1478
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CING has outperformed FBIO by 54.4 percentage points over the past year.

About Cingulate

CING stock →

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Fortress Biotech

FBIO stock →

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees

CING vs FBIO FAQ

Which is bigger, Cingulate or Fortress Biotech?

Cingulate (CING) is larger, with a market capitalization of $67.48M compared with $64.11M for Fortress Biotech (FBIO).

Which stock has performed better over the past year, CING or FBIO?

CING returned +27.76% over the past 12 months, compared with -26.64% for FBIO (price return, excluding dividends). Past performance does not predict future results.

Are Cingulate and Fortress Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons